文献速递神经肿瘤

分次伽玛刀放射外科是治疗大容积(>10 cm³)颅内脑膜瘤安全有效的方法吗?

Is Fractionated Gamma Knife Radiosurgery a Safe and Effective Treatment Approach for Large-Volume (>10 cm3) Intracranial Meningiomas?
PubMed 文献 · World Neurosurg · 2016-12-23

该回顾性研究纳入2004至2015年间70例大容积(>10 cm³)颅内脑膜瘤患者,比较单次伽玛刀与分次伽玛刀的效果与安全性。分次组5年肿瘤控制率为92.9%,单次组为88.1%,两组无进展生存率差异未达统计学显著(P=0.389);分次组症状性并发症发生率更低(P=0.017,风险比5.7:1)。

要点

  • 分次伽玛刀组5年肿瘤控制率92.9%,单次组88.1%,差异未达统计学显著(P=0.389)。
  • 分次组症状性并发症2例(7.1%),单次组14例(33.3%),分次组更低(P=0.017)。
  • 对于预计显微手术后并发症高、身体状况差的大容积脑膜瘤患者,可考虑分次伽玛刀作为替代方案。

核心结论

  • 对于预计显微手术后并发症高、且身体状况不适合手术的大容积(>10 cm³)颅内脑膜瘤患者,与单次伽玛刀相比,分次伽玛刀可获得良好的肿瘤控制且并发症率更低(P=0.017),可考虑作为替代方案。

研究设计与样本

  • 回顾性综述纳入2004至2015年间接受伽玛刀治疗的70例大容积(>10 cm³)颅内脑膜瘤患者,随访至少12个月,分为单次伽玛刀组与分次伽玛刀组,通过临床检查与系列磁共振成像随访。

主要发现

  • 单次伽玛刀组42例,中位肿瘤体积15.2 cm³(范围10.3-48.3 cm³),中位处方剂量12 Gy(范围8-14 Gy),中位随访57.8个月(范围14.5-128.4个月)。
  • 分次伽玛刀组28例,中位肿瘤体积21 cm³(范围10.2-54.7 cm³),中位处方为2次7.5 Gy(范围5-8 Gy)、3次6 Gy(范围5-6.5 Gy)及4次4.5 Gy,中位随访50个月(范围12.5-90.6个月)。
  • 分次伽玛刀组5年总体肿瘤控制率为92.9%,单次伽玛刀组为88.1%;分次组5年无进展生存率更高(92.9% vs. 88.1%),但差异未达统计学显著(P=0.389)。
  • 单次伽玛刀组症状性并发症14例(33.3%),包括偏瘫5例、癫痫4例、瘤周水肿3例及脑积水2例;分次伽玛刀组症状性并发症2例(7.1%),包括偏瘫2例。
  • 分次伽玛刀组并发症率低于单次伽玛刀组(P=0.017,风险比5.7:1)。

临床怎么用

  • 作者认为,对于预计显微手术后并发症高且身体状况差的大容积(>10 cm³)颅内脑膜瘤患者,可考虑分次伽玛刀作为替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Even with great advances in surgery and improved clinical outcome, morbidity and mortality are still high for large-volume intracranial meningiomas (MNGs). Recently, Gamma Knife radiosurgery (GKS) has proven to be a safe and effective treatment for many patients with intracranial MNGs. However, single-session GKS may increase the risk of radiation-induced toxicity for large MNGs. Recently, fractionated GKS (FGKS) has been performed for an increasing number of patients with surgically high-risk and large intracranial tumors. In this study, we report our results on the efficacy and safety of FGKS for large MNGs. METHODS: The authors performed a retrospective review of 70 patients who underwent GKS for large-volume (>10 cm3) intracranial MNGs between 2004 and 2015, with a minimum follow-up of 12 months. The authors classified these patients into 2 groups of single-session GKS, FGKS. The patients were followed by clinical examination and serial imaging with magnetic resonance imaging. RESULTS: In the single-session GKS group (42 patients), the median tumor volume was 15.2 cm3 (range 10.3-48.3 cm3); the median prescription dose was 12 Gy (range 8-14 Gy), and the median follow-up duration was 57.8 months (range 14.5-128.4 months). In the FGKS group (28 patients), the median tumor volume was 21 cm3 (range 10.2-54.7 cm3), and the median prescription was 7.5 Gy in 2 fractions (range 5-8 Gy), 6 Gy in 3 fractions (range 5-6.5 Gy), and 4.5 Gy in 4 fractions. The median follow-up duration for the FGKS group was 50 months (range 12.5-90.6 months). The overall 5-year tumor control rate was 92.9% in the FGKS group and 88.1% in the single-session GKS group. Fourteen (33.3%) symptomatic complications after single-session GKS were noted, including 5 cases of hemiparesis, 4 of seizure, 3 of peritumoral edema, and 2 of hydrocephalus. Two (7.1%) symptomatic complications after FGKS were noted, including 2 cases of hemiparesis. The FGKS group had higher progression-free survival (PFS) rate at 5 years (92.9% vs. 88.1%), but the differences did not reach statistical significance (P = 0.389). The patients in the FGKS group, however, experienced a lower complication rate compared with patients with a single-session GKS group (P = 0.017, hazard ratio, 5.7:1). CONCLUSION: When the large-volume (>10 cm3) intracranial MNGs are expected to have high morbidity after microsurgery and for patients that have a poor medical status for surgery, FGKS can be considered an alternative with good tumor control and lower complications rates compared with single-session GKS (P = 0.017).

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Han MS, Jang WY, Moon KS, et al. Is Fractionated Gamma Knife Radiosurgery a Safe and Effective Treatment Approach for Large-Volume (>10 cm3) Intracranial Meningiomas? World Neurosurg. 2016. PMID: 28017757. doi:10.1016/j.wneu.2016.12.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。